TAP
45
-5
GME
89
15
MTCH
55
5
NKE
42
2
MHK
55
2
LYB
39
2
HP
33
4
AES
61
-3
C
44
-2
FLR
50
-9
KMI
53
3
PNC
52
3
HON
58
4
ROST
63
3
PEG
57
2
PX
25
6
HCA
50
2
WEC
48
2
WAT
59
4
JBHT
42
4
TAP
45
-5
GME
89
15
MTCH
55
5
NKE
42
2
MHK
55
2
LYB
39
2
HP
33
4
AES
61
-3
C
44
-2
FLR
50
-9
KMI
53
3
PNC
52
3
HON
58
4
ROST
63
3
PEG
57
2
PX
25
6
HCA
50
2
WEC
48
2
WAT
59
4
JBHT
42
4
Financhill
Back

Sarepta Therapeutics 10K Form

Buy
55

SRPT
Sarepta Therapeutics

Last Price:
133.68
Seasonality Move:
16.32%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SRPT News And Ratings

See the #1 stock for the next 7 days that we like better than SRPT

SRPT Financial Statistics

Sales & Book Value

Annual Sales: $1.24B
Cash Flow: $-284.52M
Price / Cash Flow: 0
Annual Sales: $10.17
Price / Book: 13.14

Profitability

EPS (TTM): 0.40000
Net Income (TTM): $16.9M
Gross Margin: $1.09B
Return on Equity: 2.09%
Return on Assets: 0.54%

Sarepta Therapeutics Earnings Forecast

Key Sarepta Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 28 years for SRPT is 87.91%.
  • The Selling, General & Administrative Expenses for SRPT have been equal to 38.76% of Gross Profit Margin.
  • The Research & Development expenses have been 70.57% of Revenue.
  • The Interest Expense is -4.11% of Operating Income.
  • The Net Earning history of SRPT is -43.11% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 14 years.

Sarepta Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SRPT
CUSIP: 803607
Website: sarepta.com

Debt

Debt-to-Equity Ratio: 1.29
Current Ratio: 4.05
Quick Ratio: 2.97

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 11.71

SRPT Technical Analysis vs Fundamental Analysis

Buy
55
Sarepta Therapeutics (SRPT) is a Buy

Is Sarepta Therapeutics a Buy or a Sell?